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a b s t r a c t
Some patients with severe brain injury show short-term neurological improvements, such
as recovery of consciousness, motor function, or speech after administering zolpidem, a
GABA receptor agonist. The working mechanism of this paradoxical phenomenon remains
unknown. In this study, we used electroencephalography and magnetoencephalography to
investigate a spectacular zolpidem-induced awakening, including the recovery of func-
tional communication and the ability to walk in a patient with severe hypoxic-ischemic
brain injury. We show that cognitive deficits, speech loss, and motor impairments after
severe brain injury are associated with stronger beta band connectivity throughout the
brain and suggest that neurological recovery after zolpidem occurs with the restoration of
beta band connectivity. This exploratory work proposes an essential role for beta rhythms
in goal-directed behavior and cognition. It advocates further fundamental and clinical
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research on the role of increased beta band connectivity in the development of neuro-
logical deficits after severe brain injury.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Paradoxical signs of temporary neurological recovery have
previously been described in a subgroup of patients with se-
vere brain injury after administering zolpidem, a GABA re-
ceptor agonist (Bomalaski, Claflin, Townsend, & Peterson,
2017). This phenomenon is primarily known in patients with
disorders of consciousness, but also occurs in patients with
degenerative disorders, such as Parkinson’s disease, or those
with neurological deficits after stroke (Daniele, Panza, Greco,
Logroscino, & Seripa, 2016; Sutton & Clauss, 2017). However,
a paradoxical response to zolpidem remains rare. For
instance, in a study of a small group of patientswith a disorder
of consciousness, only 6.7% experienced signs of neurological
recovery after zolpidem (Whyte & Myers, 2009). Nonetheless,
zolpidem has gained considerable research interest in recent
years, as its action mechanism may represent a new treat-
ment for patients with a variety of neurological disorders.
Nevertheless, this action mechanism and the reason for zol-
pidem’s selective activity remain largely unknown.
Previous studies on the restorative effects of zolpidem
have suggested that the drug can restore abnormalities in
GABAergic signaling that arise after brain injury (Hall et al.,
2010, 2014; Prokic et al., 2015). Furthermore, zolpidem is
thought to temporarily suppress pathologically increased
levels of slowewave activity after brain damage that is known
to result in cognitive and motor deficits (Hall et al., 2010;
Williams et al., 2013). However, little is known about the ef-
fects of zolpidem on the mechanisms supporting large-scale
integration throughout the brain. Large-scale integration
from spatially distinct brain regions is crucial for several
cognitive functions, such as selective attention, short- and
long-term memory, and flexible routing of information
(Bosman, Lansink, & Pennartz, 2014; Fries, 2015; Varela,
Lachaux, Rodriguez, & Martinerie, 2001). Not surprisingly, a
wide variety of neurological disorders have already been
associated with dysfunctions in neuronal synchronization
(Schnitzler & Gross, 2005; Stam, 2014).
In this open-ended exploration, we set out to study the
effects of zolpidem on functional connectivity: a measure
used to characterize functional integration. We used both
EEG and MEG to study a zolpidem-induced awakening,
including the recovery of functional communication and
motor behavior in a patient with severe hypoxic-ischemic
brain injury. We report the pharmacologically-induced
neurophysiological changes paralleling this recovery and
use this evidence to propose novel hypotheses that explain
zolpidem-induced awakenings in patients with severe brain
injury.
2. Materials and methods
2.1. Ethical approval
Family members gave written informed consent to the
research protocol, which was approved by the medical ethical
committee of the Amsterdam University Medical Center
(location Academic Medical Center), The Netherlands. Ethics
review criteria conformed to the Declaration of Helsinki.
Moreover, consent was obtained for publishing video mate-
rial. No part of the study procedures or analysis planswas pre-
registered in an institutional registry prior to the research
being conducted. In the following section, we report how we
determined our sample size in the control group, all data ex-
clusions, all inclusion/exclusion criteria, whether inclusion/
exclusion criteria were established prior to data analysis, all
manipulations, and all measures in the study.
2.2. Clinical case
A man, 29-year old, with a history of alcohol abuse suffered
fromhypoxic-ischemic brain injury after choking on a piece of
meat. After an initial, though slow neurological recovery,
spontaneous movement and speech disappeared. The patient
developed such a severe impairment of arousal that he
required intensive auditory and tactile stimulation to main-
tain a wakeful state. No structural lesions were found using a
computerized tomography (CT) scan to explain this secondary
deterioration, and conventional EEG-recordings showed no
evidence of epilepsy. After a stay in the ICU and neurology
department, the patient was transferred to a nursing home
without a formal diagnosis explaining his hyporesponsive
state. A structural MRI at follow-up showed signs of diffuse
atrophy without hydrocephalus.
Eight years passed without any further improvement and
neurological follow-up. Eventually, a new nursing home
physician with experience in hyporesponsive disorders took
over the patient’s treatment and performed a new neurological
examination to find directions to improve his care. Upon clin-
ical assessment, the now 37-year old patient seemed awake,
but showed a complete lack of voluntary movement (akinesia)
and absence of speech (mutism). More specifically, the patient
showed no affective reactions, initiation of eating or drinking,
and remained incontinent. Although the patient showed no
signs of spontaneous speech or vocalization on request, hewas
able to respond to questions or commands with movements
with a significant delay (usually a couple of seconds) and with
evident ataxia and muscle rigidity. Despite his intact aware-
ness, the patient’s initiative was so severely impaired that he
remained wheelchair-bound and entirely dependent on
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nursing care for all daily activities, including the need for
enteral tube feeding. His behavioral condition was classified as
akinetic mutism (AM): a severe disorder of diminished moti-
vation (Arnts et al., 2020; Marin & Wilkosz, 2005).
After consultation with his family, a single dose of zolpi-
dem (10 mg) was administered by the nursing home physi-
cian. This dose is frequently used for patients with persistent
hyporesponsive disorders (Bomalaski et al., 2017). Within
20 min, the patient started communicating spontaneously,
asking the nurse how his wheelchair was to be operated, and
requesting fast food. He managed to walk while being sup-
ported by the staff and phoned his father, who had not heard
his son’s voice for years. Despite evident retrograde amnesia,
going back three years before the brain injury, and an
apparent hearing deficit, he was cheerful, alert, and showing
interest in the people and objects surrounding him. Twohours
after zolpidem administration, he gradually fell back into his
diminishedmotivational state. Following this observation, the
nursing home physician gave him a drug-regimen of three
daily doses of zolpidem (10 mg) around mealtimes.
However, a severe reduction in effectiveness became
noticeable after administering zolpidem for several consecu-
tive days. The time windows during which the patient was
able to talk and move got narrower, and his abilities to move
and speak during these time windows decreased. Usually, the
restorative effects of a single dose of zolpidem could be
reproduced once a day for about five consecutive days. After
this period, drug administration did not result in observable
clinical effects. The use ofmultiple doses of zolpidem during a
single day showed no improvement in his clinical condition
and sometimes even caused sedation.
On average, it would require two to three medication-free
weeks to notice the effects of a single dose of zolpidem
again. Consequently, zolpidem administration was restricted
to special occasions, such as family visits or dental appoint-
ments. With this amended pharmacological regime, a single
zolpidem dose could again lead to the effects observed after
the first administration of the drug. Under these conditions,
the effects of zolpidem became noticeable after approxi-
mately 30 min from oral administration and lasted for
30e60 min. Hereafter, a wearing-off phase followed of about
30e60 min.
At the start of the current study, the patient was 38 years
old, weighed 65 kg, and was 60 days-off of zolpidem. During
this period, the patient received no other drugs or neuro-
stimulants that could have affected his neurological
condition.
2.3. Clinical assessment
Clinical tests were performed once before and once after
zolpidem administration using the Montreal Cognitive
Assessment tool (MoCA) and Coma Recovery Scale-Revised
(CRS-R). The MoCA is a brief screening tool used for patients
with mild cognitive impairment (Nasreddine et al., 2005),
while the CRS-R is a screening tool for patients with disorders
of consciousness (Schnakers et al., 2009). These clinical tests
were performed on the same day as the EEG. Since the
maximumeffects of zolpidem lasted for a relatively short time
(approximately 30e60 min), the clinical tests were performed
only once after administration, enabling a full 30-minute
resting-state EEG recording.
2.4. EEG/MEG
2.4.1. EEG data-acquisition and pre-processing
The EEG-data were recorded in a resting-state condition with
the patient lying in bed and using a sampling frequency of
1024 Hz (Micromed, Mogliano Veneto, TV, Italy). 21 AgeCl
electrodes (19 scalp electrodes þ 2 electrodes positioned at
both ear lobes serving as recording reference) were placed
according to the international 10e20 system. Two recordings
with a duration of 30 min each were performed. The patient
was first recorded pre-zolpidem, following which zolpidem
(10 mg) was administered. Then, 30 min after the adminis-
tration of zolpidem, the patient started talking and sponta-
neously moving (became ‘awake’), after which another EEG
was recorded. From these two recording sessions, we split the
continuous EEG recording into epochs of 1-second duration.
Epochs with eyes closed were selected for both conditions.
These epochs were visually inspected to discard potential
sleep periods, and ocular and motor artifacts. Power line ar-
tifacts were eliminated using a digital notch filter (Bosman
et al., 2012). The 1-second epoching allowed us to eliminate
poor EEG segments, yet still provided an adequate frequency
resolution to accurately study low-frequency power dy-
namics. Since a relatively large number of subtle and more
substantial movement artifacts were identified, the primary
analyses of EEG (and MEG, see below) were therefore based on
selected data segments of higher quality (for an overview of
data selection, see Supplementary Figure 1). In total, we ob-
tained 286 epochs of 1-second duration (4.8 min) for the con-
dition before the administration of zolpidem and 263 epochs
of 1-second duration (4.4 min) for the condition after admin-
istration of zolpidem. For the spectral power analysis, we used
all (549 in total) artifact-free epochs of 1-second duration.
Clean epochs were digitally filtered between .5 and 100 Hz and
subsequently average referenced.
To check if our results were robust and if wewould find the
same results in subsets of our data, we performed the same
power analysis using 60 randomly selected epochs from the
total recording set for each condition. We repeated this pro-
cedure 10 times. From these 10 sets of subsampled epochs, we
obtained the power spectrum across frequencies. We report
the average and 95% CI across repetitions.
For the functional connectivity analysis, 98 and 76 artifact-
free epochs (digitally filtered between .5 and 100 Hz and sub-
sequently average referenced) were available from the pre-
and post-administration of zolpidem conditions, respectively.
The epochswere 4 s of length to be able to calculate amplitude
envelopes reliably. First, we restricted the analysis to the 30
highest-quality epochs per condition. Next, as for the power
analysis, we performed the functional connectivity analysis
for 30 randomly chosen 4-seconds epochs per condition as a
robustness-check. We repeated this procedure 10 times, also
reporting the average and 95% CI across repetitions.
2.4.2. MEG data-acquisition and pre-processing
MEG recordings were obtained in a magnetically shielded
room in a supine resting-state condition. The MEG recordings
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were performed on a separate occasion, three months after
the EEG. Two datasets of 5-minute duration each were recor-
ded pre-zolpidem. Next, the patient was administered zolpi-
dem (10 mg) outside of the magnetically shielded room. Once
again, after 30 min, the patient became awake, and two more
datasets of 5-minute duration were obtained. Data were
recorded using a 306-channel whole-head system (Elekta
Neuromag Oy, Helsinki, Finland) with a sampling frequency of
1250 Hz and online anti-aliasing (410 Hz) and high-pass
filtering (.1 Hz). The head position relative to the MEG sen-
sors was recorded continuously using the signals from five
head position indicator (HPI) coils. The HPI positions and the
outline of the patient’s scalp (around 500 points) were digi-
tized before the recording using a 3D digitizer (Fastrak, Pol-
hemus, Colchester, VT, USA). The patient’s MEG data were co-
registered to his structural MRI using a surface-matching
procedure with an estimated resulting accuracy of 4 mm
(Whalen, Maclin, Fabiani,&Gratton, 2008). This structural MRI
of the head had been obtained two months before the MEG
session as part of clinical care, using a 3T Philips MRI scanner
(Philips Medical Systems, Best, The Netherlands).
For MEG source-level analysis, the following extra pro-
cessing steps were undertaken. First, bad channels were
removed after visual inspection of the data (mean number of
excluded channels 11; range 10e12). Thereafter, the temporal
extension of Signal Space Separation (tSSS) in MaxFilter soft-
ware (Elekta Neuromag Oy, version 2.2.15) was applied using
standard settings, a correlation limit of .9, and a sliding win-
dow of 10 s (Hillebrand, Fazio, de Munck, & van Dijk, 2013;
Taulu & Simola, 2006). The automated anatomical labeling
(AAL) atlas was used to label the voxels in 78 cortical and 12
subcortical regions of interest (ROIs) (Gong et al., 2009;
Tzourio-Mazoyer et al., 2002). We used each ROI’s centroid
voxel as representative for that ROI (Hillebrand et al., 2016).
Subsequently, an atlas-based scalar beamforming approach
(beamformer, version 2.1.28; Elekta Neuromag Oy), similar to
Synthetic Aperture Magnetometry (Robinson & Vrba, 1999),
projected the sensor signals to these (source-space) centroid
voxels, resulting in a broadband (.5e48 Hz) time series for each
centroid of the 90 ROIs (Hillebrand et al., 2016). The source-
space data were visually checked for significant artifacts,
and these parts of the recording were discarded, leaving 560 s
of data pre-zolpidem administration and 550 s of data post-
zolpidem administration. Next, we visually selected the
highest-quality epochs based on the absence of small artifacts
and drowsiness (e.g., slowwaves and slow eye movements on
electrooculography).
For the power analysis, we selected 90 high-quality epochs
(1 s per epoch) per condition. As described for the EEG dataset,
we checked if our results were robust by selecting 10 sets of 60
epochs of 1-second length per condition, and reporting the
average and 95% CI across repetitions. For the functional
connectivity analysis, time-series were split into longer
epochs of 4096 samples (3.28 s). The sixty best-quality epochs
per condition (30 epochs per recording) were selected for
further analysis. Again, we performed a robustness-check by
obtaining 10 sets of 60 randomly chosen epochs (per condi-
tion) and repeating the functional connectivity analysis and
reporting the average and 95% CI across repetitions.
MEG-based functional connectivity for the patient (in both
conditions) was visually compared with the average func-
tional connectivity obtained from three healthy male volun-
teers. Three healthy volunteers were considered enough to
make an adequate comparison with our patient. The healthy
male volunteerswere 38, 40, and 41 and had all undergone one
five-minute, eyes-closed, resting-state MEG recording without
medication. Data acquisition, pre-processing, and analysis
were performed in the same way as for the patient dataset.
2.4.3. Video-recordings
Since the CRS-R has a ceiling effect in patients with disorders
of motivation, and the MoCA a floor effect, video-recordings
were performed to capture the full spectrum of behavioral
changes in our patient qualitatively. The video-recordings
were made in the nursing home of the patient in the time-
frame between the separately performed EEG and MEG
recording session.
2.5. Data analysis
For both EEG and source-space MEG data, the spectral power
was obtained using a Fast Fourier Transform (FFT) algorithm
after multitapering with 3 tapers (Mitra & Pesaran, 1999).
Given an epoch length of 1 s for the spectral analysis, this
resulted in a spectral smoothing of 8 Hz (~4 Hz from the fre-
quency center) for both datasets. Relative power values were
expressed as a percentage of the total power by dividing the
power in every frequency bin by the total power (.5e48 Hz for
MEG and 2e50 Hz for EEG) per channel/ROI. The relative band
power in each canonical frequency bandwas averaged over all
channels/ROIs and over each brain lobe (frontal, parietal,
temporal, and occipital; for MEG only). The frequency bands
were defined as theta (4e8 Hz), alpha (8e12 Hz), beta
(15e30 Hz), and gamma (30e48 Hz for MEG and 30e50 Hz for
EEG analysis).
Also, frequency band-specific functional connectivity an-
alyses were performed for both EEG (epoch length 4 s) and
MEG data (epoch length 3.2 s). Functional connectivity was
estimated using the corrected amplitude envelope correlation
(cAEC). The cAEC is a measure of functional connectivity be-
tween brain regions that corrects for the effects of volume
conduction/field spread, using a symmetric orthogonalization
procedure (Brookes,Woolrich,& Barnes, 2012; Hipp, Hawellek,
Corbetta, Siegel, & Engel, 2012). To adjust for any negative
correlations, 1 was added to all values, and the successive
numbers were divided by 2. The cAEC therefore ranges from
0 to 1, with a value of .5 indicating no connectivity. The cAEC
was calculated for all possible pairs of channels/ROIs, leading
to a 19  19 (EEG) or 90  90 (MEG) adjacency matrix that
contained the functional connectivity values between all
pairs. cAEC values were subsequently averaged per channel/
ROI (hence, indicating the functional connectivity between
one channel/ROI and all other channels/ROIs).
The observed power and cAEC between pre- and post-
zolpidem states are reported as average across epochs and
the 95% CI. The effect size of the differences in power and
cAEC between pre- and post-zolpidem states is reported using
Cohen’s d.
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The spectral and functional connectivity analyses were
performed using FieldTrip (http://www.fieldtriptoolbox.org)
(Oostenveld, Fries, Maris, & Schoffelen, 2011) in MATLAB
2016b (Mathworks; 9.1.0.441655) and in-house software
(BrainWave, version 0.9.152.12.26; CJS, available from https://
home.kpn.nl/stam7883/brainwave.html), respectively. Raw
data and source-space data with analysis code, together with
clinical assessment data and the data from the control par-




Consistent with the previously established diagnosis of aki-
netic mutism, the patient showed (inconsistent) functional
object use of more than two objects before zolpidem admin-
istration, and therefore a ceiling score on the CRS-R, indi-
cating an intact level of consciousness. 30 min after zolpidem
administration, the patient showed remarkable signs of
awakening, including the return of functional speech, spon-
taneous intentional object use, and awareness of his sur-
roundings (see Video in Supplementary Materials). Moreover,
he was able to walk several steps with some assistance. The
MoCA score improved from 0/30 to 13/30. These effects lasted
for 60 min. Hereafter, the patient gradually returned back to
his original akinetic and mute state within a period of
30e60 min.
3.2. EEG and MEG
Qualitatively, the pre-zolpidem resting-state EEG in our pa-
tient is of average voltage and shows a generalized abundance
of fast (alpha/beta) and slow (delta) activity, though without a
normal anterior-posterior differentiation (see Mendeley
dataset link for EEG’s). As in healthy individuals, drowsiness
and sleep are characterized by further slowing and K-com-
plexes, and increases of fast (alpha/beta) activity after short
verbal stimuli to arouse the patient. Post-zolpidem, the pa-
tient is muchmore awake. The background pattern is more or
less the same, with a presence of generalized fast activity
(beta) and some (frontal) theta/delta, though the EEG still lacks
a clear anterior-posterior differentiation, which is different
than in healthy persons. However, it is much faster than one
would generally expect in, for instance, a patient with en-
cephalopathy (Ebersole & Pedley, 2003).
Quantitatively, the EEG sensor-space spectral analysis of
the pre-zolpidem condition revealed a peak in relative theta
and alpha power over the frontal, and parietal cortices, which
decreased after zolpidem administration (Cohen’s d for the
contrast between conditions: theta ¼ .51, alpha ¼ 1.13). Be-
sides, a small increase in relative beta and gamma power was
observed after zolpidem administration (Cohen’s d for
beta ¼ .29, and gamma band ¼ .32), most notably over frontal,
temporal, and central/parietal regions (Fig. 1c). These differ-
ences are highlighted for the two central electrodes (Fz - Cz,
Fig. 1a), but were observed for five different groups of elec-
trodes (Supplementary Fig. 2a-e). Fig. 1b shows the average
relative power and 95% CI for the four different frequency
bands for both conditions. We subsequently performed a
robustness-check on the selected epochs, repeating (n ¼ 10)
the above analysis using 60 randomly chosen epochs across
the recording session for both conditions. The results
remained the same (Supplementary Fig. 2f-j).
The MEG source-space spectral analysis confirmed these
observations, but showed a larger effect size for the increase in
beta and gamma power (Cohen’s d for the contrast between
conditions: theta¼ .7, alpha¼ .5, beta¼ .63, and gamma¼ 1.11;
see Fig. 2 for relative power for both conditions, and
Supplementary Fig. 3 and Supplementary Table 1 for the
contrast between the two conditions). After zolpidem admin-
istration, we observed an increase in beta and gamma power
for all cortical brain regions. Interestingly, the topographical
analysis revealed that this beta power increase was most pro-
nounced for frontal and parietal regions, while temporo-
occipital regions showed higher levels of theta power pre-
zolpidem, which is followed by a shift in power towards the
alpha frequency range after the administration of zolpidem
(Fig. 2cef and Supplementary Figure 3). The robustness-check
confirmed these results (Supplementary Fig. 4).
Furthermore, we studied the functional connectivity
across different brain areas before and after the administra-
tion of zolpidem. We observed a reduction in beta band
functional connectivity throughout the brain in both the EEG
and MEG analyses (Fig. 3 and Supplementary Fig. 5). We did
not find large effect sizes for the contrast between conditions
for the other frequency bands. Therefore, we focused the rest
of our analyses on beta band functional connectivity. Inter-
estingly, the EEG analysis revealed a decrease with a medium
effect size in functional connectivity in the beta band after
administering zolpidem for most electrodes (Cohen’s d ¼ .65;
Fig. 3a). The MEG source-space cAEC analysis confirmed these
results, but showed an even larger effect size for beta (Cohen’s
d ¼ .83; Fig. 3b). We observed a decrease of beta band func-
tional connectivity across all cortical and subcortical AAL
brain regions (Fig. 3b) after zolpidem administration. These
effects were also observed in randomly chosen data segments
across the entire recording (Supplementary Fig. 5).
Finally, we compared the MEG source-space pre- and post-
zolpidem functional connectivity values with those observed
in three healthy subjects (see Fig. 3b for average cAEC and
Supplementary Fig. 6 for comparison with individual controls).
In the pre-zolpidem condition, we observed higher resting-
state functional connectivity throughout the patient’s brain
compared to the healthy controls. After zolpidem administra-
tion, this level of beta band functional connectivity in the pa-
tient decreased to levels that were comparable to those
observed in the three healthy subjects (Fig. 3b). This decrease




First, we observed that zolpidem administration in our patient
was associated with a decrease in theta/alpha power and an
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increase in beta/gamma power (see result section for effect
sizes). This power shift from low to high-frequency rhythms
corresponds with previous neurophysiological studies in
zolpidem-responsive patients with other neurological deficits
(Hall et al., 2010; Williams et al., 2013). For instance, Hall and
colleagues were the first to report that zolpidem decreases
elevated levels of low-frequency rhythms after brain injury
(Hall et al., 2010). They suggested that these specific changes
result in cognitive andmotor improvements, especially after a
stroke. Subsequently, Williams and colleagues also described
similar results in three patients with severe brain injury. They
described both a zolpidem-induced decrease of abnormal
levels of theta/alpha power, and an increase in beta power,
which is in line with the changes observed in our patient (Figs.
1 and 2). They further hypothesized that increased low-
frequency power might be a pathognomonic signature in
some patients with brain injury and considered these patients
more prone to the paradoxical effects of zolpidem. They also
proposed that a shift towards higher frequencies might be a
consequence of the restoration of inhibitory GABAergic
signaling within specific (mesocortical) neurocircuits that are
known to be involved in the regulation of arousal and
behavior (Schiff, 2010). Although we cannot mark the EEG
baseline spectral power in our patient as high or lowwithout a
control group, this mechanism might also play a role in the
restorative effects of zolpidem in akinetic mutism.
In addition to an overall shift towards higher frequencies of
the spectrum, our source-space MEG results also suggest a
peak frequency shift from theta to alpha in temporal and oc-
cipital regions (see Fig. 2def). Peak frequency shifts are
considered to reflect changes in a behavioral state (Haegens,
Cousijn, Wallis, Harrison, & Nobre, 2014; Mierau, Klimesch,
& Lefebvre, 2017). In specific, alpha power increases with
increasing cognitive demands (Handel, Haarmeier, & Jensen,
2011) and temporo-occipital alpha power fluctuations have
been associated with a flow of information in visual areas
(Jokisch & Jensen, 2007; Mazaheri, Nieuwenhuis, van Dijk, &
Jensen, 2009). The observed peak frequency shift in our pa-
tient might, therefore, reflect the transition from the akinetic
mute state to a state of increased attention and arousal (see
the video in supplementary materials for clinical overview of
attention and arousal changes).
If we specifically look at beta power, previous studies have
reported different effects of zolpidem. While some authors
report increases in beta power (Williams et al., 2013), others
report the opposite (Hall et al., 2010). Previous studies have
shown that zolpidem is capable of a bidirectional modulation
of neuronal network activity, restoring disease-specific
Fig. 1 e Effect of zolpidem on spectral power (EEG). A. Local normalized spectral power (percentage of each frequency bin
relative to the total power) from the midline (average and 95% CI, Fz and Cz electrodes) for pre- and post-zolpidem
conditions. B. Global normalized spectral power presented as bar chart per frequency band (average and 95% CI) for both
conditions. C. Head plots of the topography of normalized spectral power per frequency band, viewed from the top: theta
band, 4e8 Hz; alpha band, 8e12 Hz; beta band, 15e30 Hz; gamma band, 30e50 Hz. CI ¼ confidence interval.
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oscillatory imbalances through simultaneous augmentation
and depression of beta band activity (Hall et al., 2014).
Importantly, the actual direction of the effects of zolpidem on
oscillatory beta band activity seems to be dose-dependent
(Prokic et al., 2015). As such, zolpidem reduces beta power at
sub-sedative doses, while it increases beta-power at higher
dosages. Our patient only showed behavioral effects after
administering 10 mg of zolpidem, which is considered a
sedative dose for healthy subjects. Since our patient’s weight
was limited (65 kg), 10mgmay be a relatively high dose, which
may account for the fact that we see an overall increase in
beta power.
4.1.2. Changes in functional connectivity
The neurophysiological recordings in our patient showed a
decrease in functional connectivity in the beta band
throughout the brain after zolpidem administration (see
Fig. 3 and Supplementary Figs. 5-6). These changes were
observed in both the EEG (medium effect size) and MEG re-
cordings (large effect size), which were made with a three-
month interval. The contrast between the increase in rela-
tive beta power and decrease in functional connectivity
supports the assumption that the band power changes do
not entirely drive the functional connectivity changes.
Pathological changes in functional connectivity have been
associated with various clinical deficits in a wide variety of
brain disorders (Schnitzler & Gross, 2005; Stam, 2014;
Uhlhaas & Singer, 2006). More specifically, a pathological
increase in beta band functional connectivity is thought to be
associated with deterioration of flexible behavioral and
cognitive control (Engel & Fries, 2010). For instance, higher
beta band functional connectivity has been observed in pa-
tients with Parkinson’s disease (Bosboom et al., 2006;
McCarthy, Ching, Whittington, & Kopell, 2012). In these pa-
tients, symptom relief correlates with lowering of beta band
functional connectivity trough drug (dopamine agonist)
administration (Bosboom et al., 2006; Engel & Fries, 2010;
Silberstein et al., 2005). We suggest that the widespread
hypoxic-ischemic injury in our patient might have resulted
in a similar pathological enhancement of beta band func-
tional connectivity throughout the brain, causing abnor-
mally strong inhibition of behavioral and cognitive
functions. Administering zolpidem seems to temporarily
reverse abnormally high levels of beta band connectivity,
thereby restoring functional brain networks and improving
large-scale brain functioning.
Fig. 2 e Effect of zolpidem on source-space spectral power (MEG). A: Normalized spectral power (average and 95% CI) across
all brain regions. B: Global normalized spectral power, presented as bar chart per frequency band (average and 95% CI). CeF:
As in A., but for Frontal (C), Temporal (D), Parietal (E), and Occipital (F) brain regions. CI ¼ confidence interval. For regional
spectral power in theta, alpha, beta, and gamma bands see Supplementary Material Fig. 4.
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Recent evidence from animal studies suggests a possible
mechanism for this reversal. Brain injury, such as stroke,
might cause a shift in GABAA receptor-mediated communi-
cation as a result of injury-induced impairments of specific
GABA transporters and dysfunction in GABAA receptor sub-
units (Clarkson, Huang, Macisaac, Mody, & Carmichael, 2010;
Guerriero, Giza, & Rotenberg, 2015; Hiu et al., 2016). These
impairments eventually lead to a shift in GABAA receptor-
mediated inhibition, changing the dynamics of GABA
signaling from phasic to predominantly tonic, thereby
altering network excitability (Farrant & Nusser, 2005; Prokic
et al., 2015). Zolpidem is thought to act on GABAergic fast-
spiking interneurons that generally act to synchronize
neuronal signals across large networks, and are a crucial
component for both spectral power and functional connec-
tivity (Cardin, 2018; Chen et al., 2017; Manseau et al., 2010).
After brain injury, zolpidem seems to be able to reverse the
excessive tonic conductance in GABA interneurons,
restoring normal phasic GABA signaling and promoting
functional recovery (Clarkson et al., 2010; Hiu et al., 2016;
Prokic et al., 2015). This reversal is associated with a change
in rhythmic activities in different neuronal networks and the
Fig. 3 e Effect of zolpidem on EEG/MEG beta band functional connectivity. A. EEG functional connectivity (cAEC) per condition
for each channel (left: average and SEM) and averaged over all channels (right: average and 95% CI). B. Source-space MEG
functional connectivity (cAEC) per condition for each brain region (left: average and SEM) and averaged over all brain regions
(right: average and 95% CI). C. Beta band MEG functional connectivity for both conditions, and the contrast between
conditions, displayed on a parcellated template brain, viewed from above. For visualization purposes, only cortical brain
regions are displayed. From top to bottom: average beta band cAEC per region in the pre- and post-zolpidem condition and
effect size of beta band functional connectivity differences between pre/post-zolpidem, expressed as Cohen’s d.
SEM ¼ standard error of the mean. CI ¼ confidence interval. a ¼ anterior, p ¼ posterior. For AAL atlas regions, see
Supplementary Materials Table 2.
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regulation of synchronous population activity throughout
the brain, which may account for the changes in functional
connectivity (and spectral power) we observed in our patient.
4.2. Limitations
The above-described findings of power changes should be
interpreted cautiously. First of all, our study is subject to
performance confound, meaning that if the behavioral per-
formance is substantially different in two experimental con-
ditions (as is the case for the pre- and post-zolpidem
conditions), some measures of brain physiology might also
differ between those conditions, thereby representing an
epiphenomenon (Morales, Chiang,& Lau, 2015;Williams et al.,
2013). Neurophysiological activity is well-known to change in
different behavioral conditions. For instance, increasing
arousal is associated with clear decreases in delta, theta, and
(lower) alpha activity, whichmight explain the reduction seen
in these frequency bands in our patient (Foucher,
Otzenberger, & Gounot, 2004; Niedermeyer & Lopes da Silva,
1999). Experiments in which EEG’s were used as means to
measure cortical arousal previously even relied on the inverse
correlation of arousal with the power of low EEG frequencies
during awakening (Danos, Guich, Abel, & Buchsbaum, 2001;
Foucher et al., 2004). However, behavioral changes are usually
associated with a decrease in beta power, which is opposite of
the effects seen in our patient (Engel & Fries, 2010). Moreover,
behavioral improvements are usually accompanied by an in-
crease rather than a decrease in functional connectivity,
which suggests that the observed changes were directly
related to the observed behavioral changes (Ohara et al., 2001;
Rissman, Gazzaley, & D’Esposito, 2004). Also, it is opposite to
what is seen in other neurological disorders, such as mild
cognitive impairment and Alzheimer’s disease, where cogni-
tive and behavioral decline is associatedwith loss of beta band
synchronization (Stam, van der Made, Pijnenburg, &
Scheltens, 2003).
Furthermore, the effects observed might be similar in
healthy patients receiving zolpidem, since we lack a placebo
control in this study. For instance, it is well-known that GABA-
agonists can cause decreases in low-frequency power and
increases in beta-activity (Patat et al., 1994; Williams et al.,
2013). However, these effects on spectral power are of short-
term and variously reported in healthy patients (Perez,
Machado, Rodriguez, Estevez, & Chinchilla, 2016). Also,
behavioral improvements are usually accompanied by an in-
crease in functional connectivity, which is in contrast with the
results of our study (Ohara et al., 2001; Rissman et al., 2004).
Although we present the neurophysiological results of a
single patient, similar effects were seen in both the EEG as
MEG recordings, which were made on two different occasions
under similar conditions. The observed behavioral improve-
ments (as seen in the video), in combination with the changes
in beta functional connectivity (medium effect size for EEG
and large effect size for MEG) is quite remarkable to observe in
a single patient. However, the relative differences in effect
size between the power and functional connectivity changes
in the EEG and MEG suggests the necessity of larger sample
sizes. In contrast to the changes in beta functional connec-
tivity, the changes in beta power were smaller. Future studies
should re-examine our results in a confirmatory design (see
section 4.3) with larger samples, with a placebo control group,
and ideally controlling for performance capacity confounds
known for patients with severe brain injury (Morales et al.,
2015). Furthermore, future studies need to include a larger
group of healthy subjects to compare baseline spectral power
and functional connectivity and compare neurophysiological
findings after zolpidem administration.
4.3. Hypothesis generation
Our study suggests that patients with neurological deficits
after hypoxic-ischemic brain injury, especially those with
akinetic mutism, may maintain higher levels of beta band
functional connectivity. As mentioned above, a study with a
larger sample of patients is necessary to confirm this hy-
pothesis. This study must preferably contain patients with
similar clinical presentations and an equivalent response to
zolpidem to prevent bias, though this may be challenging
since zolpidem awakenings remain rare (Arnts et al., 2020;
Whyte & Myers, 2009). Therefore, international collaboration
and the clustering of cases in specialized centers will be
necessary actions for further research.
Our study also suggests that zolpidem can temporarily
reduce and restore beta band functional connectivity to a level
that allows functionality to return. Interestingly,Williams and
colleagues demonstrated a subtle increase in frontal inter-
hemispheric coherence within the 20e30 Hz range in two of
their three patients.More recently, Sripad and co-workers also
described similar results in another case-study (Sripad et al.,
2020). An explanation for the difference with our case (i.e.,
increased versus decrease beta band connectivity) may be
found in the fact that all of these patients experienced brain
injury from traumatic origin. Therefore, additional studies,
including patients with different types of brain injury, both
from traumatic and hypoxic-ischemic origins, are necessary
to clarify these contradicting results. These studies should
also include a treatment schedule with low- and high-dose
zolpidem to reveal what the real dose-dependent effects are
of zolpidem in human subjects (Prokic et al., 2015).
Further insights into the action mechanisms of zolpidem
might eventually lead to new treatment strategies for patients
with severe brain injury. For instance, if a reduction in beta
band functional connectivity also relates to functional
improvement in other patients with brain injury, it is
conceivable to think that therapies that reduce beta band
connectivity might be beneficial for a larger group of patients.
These therapies may include a variety of dopamine agonists,
or invasive treatments that are known to more permanently
affect beta band functional connectivity, such as deep brain
stimulation (Boon et al., 2020).
Beta rhythms are traditionally associated with sensori-
motor functions. However, they have recently become more
broadly implicated in top-down processing, long-range
communication, and other cognitive functions (Bastos
et al., 2015). Our findings contribute to an increasing corpus
of evidence that demonstrates a complex role for beta os-
cillations in the coordination of the flow of information
across brain areas (Spitzer & Haegens, 2017). Future animal
and human studies should elucidate how brain injuries could
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affect the functionality of beta oscillations in cortical
microcircuit regulation, top-down processing, and long-
range communication.
5. Conclusion
Overall, our findings suggest an essential role of the beta band
in goal-directed behavior and cognition. Our results also
advocate further fundamental and clinical research on the
role of beta band functional connectivity in the development
of neurological deficits after severe brain injury, as this may
lead to new therapeutic strategies.
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